On April 5, 2024 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, reported that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP) (Press release, Immunome, APR 5, 2024, View Source [SID1234641831]). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, which is taking place April 5-10 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"FAP is an attractive target for cancer therapy, but trials with first-generation FAP-RLTs have produced modest clinical responses, indicating the need for novel agents with improved therapeutic properties," commented Dr. Higgins. "We believe IM-3050 has best-in-class potential and look forward to sharing preclinical data for the program at AACR (Free AACR Whitepaper)."
Immunome expects to submit an Investigational New Drug application to the U.S. Food & Drug Administration for IM-3050 in the first quarter of 2025.
Poster Presentation Details:
Title: A novel lutetium-177 radioligand therapy targeting FAP has potent antitumor activity in xenograft cancer model (Abstract #6026)
Presenter: Jack Higgins, PhD, Chief Scientific Officer
Date: April 9, 2024 1:30 p.m. – 5:00 p.m. PDT
A copy of the poster will be available on the Events & Presentations section of Immunome’s website following the conference.